Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Natalia I. Khalaf

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-7585-6183; OpenAlex author ID A5037464744; NIH RePORTER profile ID 14834704. Sources: OpenAlex.

Their work

Papers
26 (first author 2, last author 0)
Trials
0
Grants
1
Labs led
0
Collaborators
77
Papers, trials and grants by year

2017: 1 paper · 2018: 4 papers · 2019: 5 papers · 2020: 3 papers · 2021: 2 papers · 2022: 2 papers · 2023: 2 papers · 2024: 4 papers · 2025: 1 paper · 2026: 2 papers, 1 grant

Papers 26

  1. A digital quality measure for emergency presentation of pancreatic cancer. Co-author DOI 10.1038/s41416-026-03343-y↗
  2. Enriching New-onset Diabetes for Pancreatic Cancer (ENDPAC): external validation using English sentinel network. Co-author DOI 10.3399/bjgp.2024.0253↗
  3. Defining and Understanding Diagnostic Delays Among Pancreatic Cancer Patients: A Retrospective Cohort Study. Co-author DOI 10.1016/j.cgh.2024.07.006↗
  4. Emergency Presentations Predict Worse Outcomes Among Patients with Pancreatic Cancer. Co-author DOI 10.1007/s10620-023-08207-6↗
  5. The Impact of Race on Pancreatic Cancer Treatment and Survival in the Nationwide Veterans Affairs Healthcare System. Co-author DOI 10.1097/mpa.0000000000002272↗
  6. External UK validation of the ENDPAC model to predict pancreatic cancer risk: A registered report protocol Co-author DOI 10.1101/2024.05.21.24307690↗
  7. Determining the feasibility of calculating pancreatic cancer risk scores for people with new-onset diabetes in primary care (DEFEND PRIME): study protocol. Co-author DOI 10.1136/bmjopen-2023-079863↗
  8. Diabetes Status and Pancreatic Cancer Survival in the Nationwide Veterans Affairs Healthcare System. Co-author DOI 10.1007/s10620-023-08035-8↗
  9. Adipose tissue and skeletal muscle wasting precede clinical diagnosis of pancreatic cancer. Co-author DOI 10.1038/s41467-023-40024-3↗
  10. New-onset Diabetes as a Signpost of Early Pancreatic Cancer: The Role of Screening Co-author DOI 10.1016/j.cgh.2022.02.015↗
  11. Challenges and Opportunities in Pancreatic Cancer Screening Among High-Risk Individuals Co-author DOI 10.1053/j.gastro.2022.03.040↗
  12. Burden of Pancreatic Cancer: From Epidemiology to Practice. Co-author DOI 10.1016/j.cgh.2020.02.054↗
  13. Prediagnostic Inflammation and Pancreatic Cancer Survival. Co-author DOI 10.1093/jnci/djab040↗
  14. Diabetes, Weight Change, and Pancreatic Cancer Risk. Co-author DOI 10.1001/jamaoncol.2020.2948↗
  15. The Influence of Gut and Tumor Microbiome on Pancreatic Cancer Outcomes. Co-author DOI 10.1053/j.gastro.2020.07.008↗
  16. Imaging-Based Subtypes of Pancreatic Ductal Adenocarcinoma Exhibit Differential Growth and Metabolic Patterns in the Pre-Diagnostic Period: Implications for Ea… Co-author DOI 10.3389/fonc.2020.596931↗
  17. Family history of cancer, Ashkenazi Jewish ancestry, and pancreatic cancer risk. Co-author DOI 10.1038/s41416-019-0426-5↗
  18. Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Co-author DOI 10.1038/s41436-018-0009-5↗
  19. Metabolic Alterations as a Signpost to Early Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2019.03.028↗
  20. Postdiagnosis Loss of Skeletal Muscle, but Not Adipose Tissue, Is Associated with Shorter Survival of Patients with Advanced Pancreatic Cancer. Co-author DOI 10.1158/1055-9965.epi-19-0370↗
  21. Prediagnostic Leukocyte Telomere Length and Pancreatic Cancer Survival. Co-author DOI 10.1158/1055-9965.epi-19-0577↗
  22. Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamaoncol.2017.3420↗
  23. Statin use and pancreatic cancer risk in two prospective cohort studies. First author DOI 10.1007/s00535-018-1430-x↗
  24. Prediagnosis Use of Statins Associates With Increased Survival Times of Patients With Pancreatic Cancer. First author DOI 10.1016/j.cgh.2018.02.022↗
  25. Regular Use of Aspirin or Non-Aspirin Nonsteroidal Anti-Inflammatory Drugs Is Not Associated With Risk of Incident Pancreatic Cancer in Two Large Cohort Studie… Co-author DOI 10.1053/j.gastro.2017.12.001↗
  26. Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival. Co-author DOI 10.1038/bjc.2017.349↗

Grants 1

  1. Health informatics approaches to reduce missed opportunities in diagnosis of pancreatic cancer IK2HX003346↗

Closest collaborators

The 25 strongest of 77 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hardeep Singh · 5 shared papers, 2023–2026 · strength 1.33
  2. Hashem B. El‐Serag · 6 shared papers, 2020–2025 · strength 1.33
  3. Brian Matthew Wolpin · 14 shared papers, 2017–2023 · strength 1.19
  4. Fasiha Kanwal · 5 shared papers, 2020–2025 · strength 1.14
  5. Basim Ali · 3 shared papers, 2022–2024 · strength 0.90
  6. Ana Babić · 11 shared papers, 2017–2023 · strength 0.84
  7. Kimmie Ng · 11 shared papers, 2017–2023 · strength 0.84
  8. Chen Yuan · 11 shared papers, 2017–2023 · strength 0.83
  9. Hugh Claridge · 3 shared papers, 2024–2026 · strength 0.73
  10. Simon de Lusignan · 3 shared papers, 2024–2026 · strength 0.73
  11. Claire A. Price · 3 shared papers, 2024–2026 · strength 0.73
  12. Agnieszka Lemańska · 3 shared papers, 2024–2026 · strength 0.73
  13. Charles S. Fuchs · 10 shared papers, 2017–2021 · strength 0.70
  14. Vicente Morales‐Oyarvide · 10 shared papers, 2017–2021 · strength 0.68
  15. Jonathan Andrew Nowak · 9 shared papers, 2017–2023 · strength 0.66
  16. Edward L. Giovannucci · 7 shared papers, 2018–2021 · strength 0.55
  17. Peter Kraft · 7 shared papers, 2018–2021 · strength 0.55
  18. Douglas Adam Rubinson · 7 shared papers, 2017–2020 · strength 0.46
  19. Yan Liu · 2 shared papers, 2023–2024 · strength 0.43
  20. Michael Hayden Rosenthal · 4 shared papers, 2019–2023 · strength 0.37
  21. Tsuyoshi Hamada · 5 shared papers, 2018–2019 · strength 0.35
  22. Andrew J. Aguirre · 4 shared papers, 2018–2023 · strength 0.33
  23. Zhi Rong Qian · 5 shared papers, 2017–2019 · strength 0.29
  24. Matthew B.B. Yurgelun · 3 shared papers, 2019–2023 · strength 0.27
  25. Kimberly J. Perez · 3 shared papers, 2019–2021 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.